Back to results
US 12,576,069 B2Granted
Compositions and methods for treating slow-flow vascular malformations
AssigneeYale University
InventorsNaiem Nassiri, Prashant Patel
Life of this patent
Estimating the term…
Abstract
The disclosure relates in part to the discovery that slow-flow vascular malformations (which can be venous and/or lymphatic) can be treated using direct intralesional delivery of an active drug, such as but not limited to a mTOR inhibitor, such as but not limited to temsirolimus, or a salt or solvate thereof.
Claims17
A dose unit of a mTOR inhibitor,
- wherein the dose unit is sterile,
- wherein the dose unit comprises a contrast dye,
- wherein the mTOR inhibitor is selected from the group consisting of BEZ235, everolimus, AZD8055, Temsirolimus, KU-0063794, PI-103, Torkinib, Tacrolimus, Ridaforolimus, INK-128, Voxtalisib, Torin-1, Omipalisib, OSI-027, PF-04691502, Apitolisib, GSK1059615, WYE-354, Gedatolisib, AZD-2014, Torin-2, WYE-125132, BGT226, Palomid-529, PP121, WYE-687, CH5132799, Way-600, ETP-46464, GDC-0349, XL388, and Zotarolimus, or a salt, solvate, enantiomer, or diastereoisomer thereof,
- wherein the mTOR inhibitor is in a solution, or can be dissolved in a solvent to form a solution, and
- wherein the mTOR inhibitor concentration in the solution ranges from about 0.5 mg/ml to about 5 mg/ml.
2 more elements
A method of treating or ameliorating at least one of a congenital vascular malformation, Klippel-Trenaunay syndrome, CLOVES syndrome, and Proteus syndrome in a subject,
- wherein the method comprises intralesionally administering to the subject a therapeutically effective amount of a mTOR inhibitor,
- wherein the mTOR inhibitor is selected from the group consisting of BEZ235, everolimus, AZD8055, Temsirolimus, KU-0063794, PI-103, Torkinib, Tacrolimus, Ridaforolimus, INK-128, Voxtalisib, Torin-1, Omipalisib, OSI-027, PF-04691502, Apitolisib, GSK1059615, WYE-354, Gedatolisib, AZD-2014, Torin-2, WYE-125132, BGT226, Palomid-529, PP121, WYE-687, CH5132799, Way-600, ETP-46464, GDC-0349, XL388, and Zotarolimus, or a salt, solvate, enantiomer, or diastereoisomer thereof.
Dependencies are inferred from the claim text.